The Novel Cholesterol-lowering Drug SR-12813 Inhibits Cholesterol Synthesis via an Increased Degradation of 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase

This publication has 27 references indexed in Scilit:

• SK&F 99085/SR-9223i, a novel hypocholesterolemic agent with multiple anti-atherosclerotic properties, lowers plasma cholesterol in normocholesterolemic animals
  Atherosclerosis, 1994
• Mevalonate-mediated suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase function in alpha-toxin-perforated cells.
  Proceedings of the National Academy of Sciences, 1994
• Modulation of 3-hydroxy-3-methylglutaryl-CoA reductase by 15 alpha-fluorolanost-7-en-3 beta-ol. A mechanism-based inhibitor of cholesterol biosynthesis.
  Journal of Biological Chemistry, 1993
• Distinct sterol and nonsterol signals for the regulated degradation of 3-hydroxy-3-methylglutaryl-CoA reductase.
  Published by Elsevier ,1992
• Growth requirements and expression of LDL receptor and HMG-CoA reductase in Hep G2 hepatoblastoma cells cultured in a chemically defined medium
  Journal of Cell Science, 1992
• Regulation of HMG-CoA reductase: identification of the site phosphorylated by the AMP-activated protein kinase in vitro and in intact rat liver.
  The EMBO Journal, 1990
• Regulation of the mevalonate pathway
  Nature, 1990
• Hep G2 cells as a resource for metabolic studies: lipoprotein, cholesterol, and bile acids
  The FASEB Journal, 1990
• Progress in understanding the LDL receptor and HMG-CoA reductase, two membrane proteins that regulate the plasma cholesterol
  Journal of Lipid Research, 1984
• Regulation of HMG-CoA Reductase
  Published by Elsevier ,1976